Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06191991 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)
A Phase 1 study, sponsored by Aligos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT06191991 is a Phase 1 study that has completed, run by Aligos Therapeutics. The registered enrollment target is 14 participants.
The verdict
NCT06191991, a Phase 1 study, has completed, sponsored by Aligos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This Phase 1 study consists of two parts, all conducted in healthy volunteers (HVs). In Parts 1 and 2, the drug-drug interaction (DDI) potential of ALG-055009 will be explored, where subjects will be assigned to receive multiple doses of ALG-055009 and 2 single doses of one of the following concomitant drugs: atorvastatin (Part 1), or rosuvastatin (Part 2, optional).
Interventions
- DRUG Rosuvastatin
- DRUG Atorvastatin
- DRUG ALG-055009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2023-11-03 |
| Est. Completion | 2023-12-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06191991
The ClinicalTrials.gov registry entry for NCT06191991 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aligos Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rosuvastatin is the first listed.
NCT06191991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06191991 about?
NCT06191991 is a clinical study titled "A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)". This Phase 1 study consists of two parts, all conducted in healthy volunteers (HVs). In Parts 1 and 2, the drug-drug interaction (DDI) potential of ALG-055009 will be explored, where subjects will be assigned to receive multiple doses of ALG-055009 and 2 single doses of one of the following concomit...
What is the current status of trial NCT06191991?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2023-11-03. Estimated completion is 2023-12-04.
What interventions are being tested in trial NCT06191991?
The interventions under investigation include: Rosuvastatin (DRUG), Atorvastatin (DRUG), ALG-055009 (DRUG).
Who is sponsoring clinical trial NCT06191991?
This trial is sponsored by Aligos Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.